Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 133,286 shares, an increase of 195.0% from the March 15th total of 45,179 shares. Currently, 0.8% of the shares of the stock are short sold. Based on an average daily volume of 160,424 shares, the days-to-cover ratio is currently 0.8 days.

Genenta Science Stock Performance

Shares of Genenta Science stock traded down $0.03 during trading on Monday, reaching $0.64. 49,417 shares of the stock traded hands, compared to its average volume of 954,455. The company has a current ratio of 14.16, a quick ratio of 14.16 and a debt-to-equity ratio of 0.35. Genenta Science has a 52-week low of $0.59 and a 52-week high of $10.00. The business has a fifty day simple moving average of $0.82 and a two-hundred day simple moving average of $1.67.

Genenta Science (NASDAQ:GNTA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.28. On average, equities research analysts anticipate that Genenta Science will post -0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genenta Science in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Genenta Science currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Eurizon Capital SGR S.p.A. purchased a new stake in Genenta Science during the fourth quarter valued at $536,000. Ghisallo Capital Management LLC purchased a new stake in shares of Genenta Science during the 4th quarter valued at about $482,000. Weiss Asset Management LP bought a new position in shares of Genenta Science in the 4th quarter valued at about $480,000. Norges Bank purchased a new position in Genenta Science in the fourth quarter worth about $337,000. Finally, Alyeska Investment Group L.P. purchased a new position in Genenta Science in the fourth quarter worth about $328,000. 15.13% of the stock is owned by hedge funds and other institutional investors.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.